Left sidebar

Lorem Ipsum is simply dummy text of the printing.
Posted by The Analyst | 23 May 2020 | Breaking News
Herd immunity tactics now look very flawed

There are currently fewer than 2,000 people in the State who have "active" coronavirus infection.

Continue Reading
Posted by The Analyst | 23 May 2020 | Breaking News
Family of Khashoggi ‘forgives’ his killers

The sons of murdered journalist Jamal Khashoggi say they have forgiven their father's killers - a declaration that could allow Saudi authorities to commute the death sentences of five Saudi officials convicted of Mr Khashoggi's assassination.

Continue Reading
Posted by The Analyst | 23 May 2020 | Breaking News
Chartering a course: Paul Henry elected president of Accountants Ireland, vows key role in recovery

Chartered Accountants Ireland has elected Paul Henry president for 2020-21 at its 132nd AGM, held virtually for the first time.

Continue Reading
Posted by The Analyst | 23 May 2020 | Breaking News
Aer Lingus staff facing further pay cuts and swathe of redundancies

Aer Lingus employees are to be told next week of additional cuts to pay and working hours as well as redundancies.

Continue Reading
Posted by The Analyst | 23 May 2020 | Breaking News
‘Petulant child’ president hits out after refusal to wear a mask

Donald Trump lashed out at Michigan attorney general Dana Nessel in a pair of late-night tweets after she called him "a petulant child".

Continue Reading
Posted by The Analyst | 23 May 2020 | Breaking News
‘Game-changer’ drug hailed by Trump is ‘more likely to kill’

A study of 96,000 hospitalised coronavirus patients on six continents found those who received an antimalarial drug promoted by President Donald Trump as a "game-changer" in the fight against the virus had a significantly higher risk of death.

Continue Reading
Posted by The Analyst | 23 May 2020 | Breaking News
‘Encouraging’ signs in early trial of possible Covid vaccine

A new coronavirus vaccine which has safely triggered an immune response to the lethal infection in its first phase trial has been described as "encouraging".

Continue Reading